Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy

• Published in: Journal of cancer research and clinical oncology Vol. 147; no. 12; pp. 3653 - 3664
• Main Authors: Zhao, Yuxin, Wang, Haiyong, He, Chengwei
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2021; Springer Nature B.V
• Subjects: Antineoplastic Agents - therapeutic use; c-Met protein; Cancer Research; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Chemotherapy; Cytotoxicity; Drug delivery; Drug resistance; Drug Resistance, Neoplasm - physiology; Epidermal growth factor; Epidermal growth factor receptors; ErbB protein; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB-2 protein; Hematology; Hepatocyte growth factor; Humans; Insulin; Insulin-like growth factor I; Internal Medicine; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medicine; Medicine & Public Health; Mesenchyme; Molecular Targeted Therapy - methods; Mutation; Non-small cell lung carcinoma; Oncology; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; PTEN protein; Review – Clinical Oncology; Small cell lung carcinoma; Stat3 protein; Tensin; Transcription activation; Tumors; Vascular endothelial growth factor; Drug resistance; Targeted therapy; Non-small cell lung cancer; Epidermal growth factor receptor-tyrosine kinase inhibitor

Purpose Non-small cell lung cancer (NSCLC) accounts for about 85% in all cases of lung cancer. In recent years, molecular targeting drugs for NSCLC have been developed rapidly. The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have changed the paradigm of cancer therapy fro...